Cancer Research

Mikhail Blagosklonny Dedicates His Work Towards Life Extension

Mikhail Blagosklonny is an oncology professor for the Roswell Park Cancer on nature.com. He studied for his medical degree at the First Pavlov State Medical University of St. Peterburg. He also went on to teach at the New York Medical College.

His first major position was at the Ordway Research Institute as a senior scientist. He finally moved on to the Roswell Park Cancer Institute to study cancer and aging related diseases. Much of his work has been studying drugs in relation to theoretical life extension.

Mikhail is popularly known for his unusual theory of the role of TOR signaling in aging. He has suggested that the usage of Sirolimus(rapamycin) can be used to directly reduce the aging process. This drug is typically used during organ transplants and for experimental cancer treatments on tandfonline.com. There is still much debate around this theory to this day.

Mikhail Blagosklonny produces many publications in relation to hematology, clinical trials and oncology. A recent publication was about his research on how Dual MTORC1/C2 inhibitors can reduce cellular geroconversion. He also analyzed a rat study that proves that Sirolimus reduces benign prostate hyperplasia in rats.

Mikhail Blagosklonny had also made an interesting publication discussing the relationship between calorie restriction and longevity. He named this paper Koschei the immortal and anti-aging drugs. Koschei was an immortal person that was very popular in Norther European and Slavic folklore that ate very little and had a bony body. He also discusses the benefits of combing Sirolimus, metformin and other theoretical life extending drugs with calorie restriction.

He also oversaw the study of rats being fed a high fat diet and used rapamycin to prevent fat gain. The study showed that the rats eating a high fat diet gained a lot of weight at the low fat diet prevented any weight gain. Source: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=3740